Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Intellectual Disability × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 87 Carcinoma, Renal Cell 63 Neoplasm Metastasis 38 Neoplasms 32 Neuroendocrine Tumors 31 Kidney Neoplasms 24 Recurrence 16 Carcinoma, Non-Small-Cell Lung 16 Tuberous Sclerosis 14 Prostatic Neoplasms 14 Triple Negative Breast Neoplasms 13 Head and Neck Neoplasms 12 Glioblastoma 12 Carcinoma, Hepatocellular 12 Pancreatic Neoplasms 11 Lymphoma, Mantle-Cell 11 Lymphoma 11 Brain Neoplasms 11 Lymphoma, Large B-Cell, Diffuse 10 Leukemia, Lymphocytic, Chronic, B-Cell 10 Hodgkin Disease 10 Colorectal Neoplasms 10 Carcinoma, Neuroendocrine 10 Sarcoma 9 Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Glioma 9 Waldenstrom Macroglobulinemia 8 Lymphoma, Follicular 8 Lung Neoplasms 8 Carcinoid Tumor 8

Interventions

Restraint, Physical 1 Population Groups 1 Play Therapy 1 Magnetoencephalography 1 Everolimus 1 Educational Status 1 Control Groups 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01730209 2015-05-05

RAPIT

Erasmus Medical Center

Phase 2/3 Unknown

Autistic Disorder, Intellectual Disability, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡